Novel Ablation Catheters for Atrial Fibrillation.

Various ablation technologies with different energy sources are currently being either used or being investigated for atrial fibrillation (AF) ablation. Potential complications continue to occur due to the indiscriminate thermal effects on non-targeted tissues adjacent to the myocardium that are common to all thermal ablation modalities. Pulsed field ablation (PFA) has recently gained significant attention and interest as an approach to AF ablation. PFA uniquely has the ability to circumvent certain complications related to thermal energy. PFA is a non-thermal ablation modality with the potential for unique-tissue selectivity that can minimize damage to collateral cardiac structures. Several PFA systems for AF ablation are currently being investigated. Some PFA systems have been designed to serve as single-shot approaches to achieve pulmonary vein isolation (PVI), and others have focal designs enabling flexible PVI lesion sets as well as linear/focal ablations. Favorable acute success rates and low incidence of complications with short procedure times have been reported with several PFA systems regardless of catheter design (single-shot or focal catheter). Clinical PFA studies in which chronic remapping was conducted, demonstrated pulmonary vein (PV) durability improved with evolutional modifications of pulsed field waveforms/dosing, achieving over 90% PV durability with optimized waveforms. Rare adverse events related to PFA may surface with its increasing use worldwide and as sicker patients get exposed to PFA. We believe that both excitement and vigilance are in order as we embark on yet another new chapter of AF ablation.

Informations de copyright

Copyright: © 2024 The Author(s). Published by IMR Press.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest. Affera-Metronic (Consultant, Equity, Research grant), Abbott (Consultant), Cardiofocus (Consultant, Research grant), Farapulse-Boston Scientific (Consultant, Research grant). Jacob Koruth’s disclosures include Abbott (Consultant), Affera (Consultant, Equity, Research grant), Cardiofocus (Consultant, Research grant), Farapulse (Consultant, Research grant), Pulse Biosciences (Consultant, Research grant).